We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Good prognostic factor in patients with nonmetastatic nasopharyngeal carcinoma: Programmed death ligand‑1 expression in tumor cells.
- Authors
Şahinli, Hayriye; Akyürek, Nalan; Yılmaz, Mukaddes; Kandemir, Olcay; Duran, Ayşe Ocak; Kulaçoğlu, Sezer; Uçar, Gökhan; Acar, Elif; Özet, Ahmet; Berna, Ö.; Öksüzoğlu, Ç.; Özdemir, Nuriye Y.
- Abstract
Purpose: Programmed death ligand‑1 (PD‑L1) is the main ligand for programmed death‑1 (PD‑1), and is one of the major targets for cancer immunotherapy. Only a few studies are available for the clinical significance of PD‑1/PD‑L1 in nasopharyngeal carcinoma (NPC). There is a controversial association between PD‑L1 expression and survival in NPC. This study aimed at defining any potential association between PD‑L1 expression in tumor cells (TCs) and prognosis in NPC. Patients and Methods: A total of seventy NPC patients treated between January 2008 and December 2016 were included in the study. PD‑L1 expression was assessed by immunohistochemistry (IHC) in tumor specimens. The IHC assay was considered positive if ≥5% of TCs are stained. Clinicopathological variables were documented. Variables included in the analysis were PD‑L1 expression, clinicopathological characteristics, and prognosis. Results: The estimated 5‑year overall survival (OS) rate was 62%. Nearly 55.7% (n = 39) of the TCs tested positive for PD‑L1 expression. No associations were found between the level of PD‑L1 in TCs and clinicopathological characteristics. Comparisons between patients with PD‑L1‑positive tumors and PD‑L1‑negative tumors revealed that OS was statistically significantly longer in patients with PD‑L1‑positive tumors as assessed by the univariate Cox regression analysis(hazard ratio [HR], 0.378; 95% confidence interval, 0.158–0.905; P = 0.029) and Kaplan–Meier curves (P = 0.023). Conclusion: PD‑L1 expression is an important prognostic factor in NPC. PD‑L1 expression positively correlates with survival.
- Subjects
PROGNOSIS; NASOPHARYNX cancer; OVERALL survival; PROGRAMMED cell death 1 receptors; PROGRAMMED death-ligand 1; NASOPHARYNX tumors
- Publication
Journal of Cancer Research & Therapeutics, 2020, Vol 16, pS43
- ISSN
0973-1482
- Publication type
Article
- DOI
10.4103/jcrt.JCRT_759_19